A perspective on erythropoietin as a potential adjuvant therapy for acute lung injury/acute respiratory distress syndrome in patients with covid-19
Fecha
2020Autor
Sahebnasagh, Adeleh
Mojtahedzadeh, Mojataba
Najmeddin, Farhad
Najaf, Atabak
Safdari, Mohammadreza
Rezai Ghaleno, Hassan
Habtemariam, Solomon
Berindan Neagoe, Ioana
Mohammad Nabavi, Seyed
Documentos PDF
Imagenes y Videos
Resumen
The novel coronavirus 2019-nCoV (SARS-CoV-2) infection that emerged in China in
December 2019 has rapidly spread to become a global pandemic. This article summarizes
the potential benefits of erythropoietin (EPO) in alleviating SARS-CoV-2 pathogenesis
which is now called COVID-19. As with other coronavirus infection, the lethality of
COVID-19 is associated with respiratory dysfunction due to overexpression of proinflammatory cytokines induced by the host immune responses. The resulting cytokine storm
leads to the development of acute lung injury/acute respiratory distress syndrome
(ALI/ARDS). Erythropoietin, well known for its role in the regulation of erythropoiesis,
may have protective effects against ALI/ARDS induced by viral and other pathogens.
EPO exerts antiapoptotic and cytoprotective properties under various pathological conditions. With a high safety profile, EPO promotes the production of endothelial progenitor
cells and reduce inflammatory processes through inhibition of the nuclear factor-kB (NFkB) and JAK-STAT3 signaling pathways. Thus, it may be considered as a safe drug
candidate for COVID-19 patients if given at the early stage of the disease. The potential
effects of erythropoietin on different aspects of ALI/ARDS associated with SARS-CoV-2
infection are reviewed.
Palabras clave
COVID-19; Global pandemic; Respiratory distress syndrome; 2019-nCoVEnlace al recurso
https://doi.org/10.1016/j.arcmed.2020.08.002Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.